Details of the Drug Formulations

General Information of Drug (ID: DM6OC53)

• Drug Name: PDX-101 Drug Info
• Synonyms: Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684

Indication

Disease Entry	ICD 11	Status	REF
Plasma cell myeloma	2A83.1	Approved	[1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified		Approved	[1]
Primary cutaneous T-cell lymphoma		Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Haematological malignancy	2B33.Y	Phase 1	[3]
Peripheral T-cell lymphoma	2A90.C	Phase 1	[3]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 6918638
  ChEBI ID: CHEBI:61076
  CAS Number: 866323-14-0
  TTD ID: D0XT6W
  VARIDT ID: DR00787
  INTEDE ID: DR0184
  ACDINA ID: D00866

Full List of Drug Formulations Containing This Drug

Belinostat 500mg/vial powder

Company	Formulation ID	FDA Description
Acrotech	F23081	L-Arginine

References

• [1] Belinostat FDA Label
• [2] A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)